#5505 EFFICACY OF PAXLOVID WITHIN 5 DAYS VERSUS 5 DAYS AFTER DIAGNOSIS IN COVID-19 PATIENTS WITH CHRONIC KIDNEY DISEASE

Abstract Background and Aims With the liberalization of COVID-19 control policies in mainland China, majority Chinese population has experienced Omicron infection since mid-December 2022. Paxlovid is a commonly used antiviral drug for patients with COVID-19, but there are few studies chronic kidney disease (CKD).Therefore, we conducted retrospective cohort study to explore efficacy CKD at different time points after infection. Method 70 who were admitted Department Nephrology, Third Affiliated Hospital Southern Medical University before January 07, 2023 diagnosed included.The divided into three groups: No group, group within 5 days diagnosis, each patient was followed-up least 4 weeks. The primary outcome measures included all-cause mortality, length hospital stay, PCR positive duration aggravation requires ICU admission or mechanical ventilation, initiation renal replacement therapy, re-hospitalization. t test non-parametric compare quantitative data, chi-square rates, K-M curve Cox regression model survival analysis. Results Among (mean age 65.8±15.90 years, male sex 67.7%), not 35 (50%), 16 (22.9%) 19 (27.1%) days. At start follow-up, no significant differences age, gender, eGFR, comorbidities, severity laboratory parameters between diagnosis. However, had more severe than those did use (P<0.001), likely glucocorticoids (74.3% vs 17.1%, P< 0.001), as well lower lymphocyte count (0.54*10^9/L 0.85*10^9/L, P = 0.016) percentage (9.5% 14.2%, 0.009), Higher levels IL-6 (68.57 pg/ml 14.66 pg/ml, 0.015) CRP(113.36 mg/L 24.57 mg/L, 0.001). After median follow-up 45 days, found that significantly longer stays higher rehospitalization subgroup analysis finding increased stay rates mainly attributable Patients nucleic acid (25 7 0.001) (16 10 0.008) compared earlier. end total nine died. drawn exclusion mild patients, which showed lowest risk death, highest fell between. due small sample size, difference statistically (P 0.155). (HR 1.009; 95% CI: 1.004-1.014, 0.001)was best predictor death adjusting other factors. Conclusion infected general population. Early inhibit virus replication good therapeutic effect on these can greatly reduce emergency therapy. Delayed may increase stay.